P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma
Paul G. Richardson,Constantine S. Mitsiades,Jacob P. Laubach,Roman Hájek,Ivan Spicka,Meletios A. Dimopoulos,Philippe Moreau,David S. Siegel,Sundar Jagannath,Kenneth C. Anderson +9 more
TL;DR: Clinical evidence demonstrates that treatment with HDAC inhibitors in combination with other antimyeloma agents has promising antitumor activity in relapsed/refractory multiple myeloma patients.
Journal ArticleDOI
Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.
Constantine S. Mitsiades,Cecile Rouleau,Cinara Echart,Krishna Menon,Beverly A. Teicher,Maria Distaso,Antonio Palumbo,Mario Boccadoro,Kenneth C. Anderson,Massimo Iacobelli,Paul G. Richardson +10 more
TL;DR: Defibrotide's in vivo chemosensitizing properties and lack of direct in vitro activity against tumor cells suggest that it favorably modulates antitumor interactions between bone marrow stromal cells and endothelia in the tumor microenvironment.
Journal ArticleDOI
Pharmacokinetics and Safety of Tenofovir in HIV-Infected Women During Labor and Their Infants During the First Week of Life
Mark Mirochnick,Taha E. Taha,Regis Kreitchmann,Karin Nielsen-Saines,Newton Kumwenda,Esau Joao,Jorge Pinto,Breno Santos,Teresa L. Parsons,Brian P. Kearney,Lynda Emel,Casey M. Herron,Paul G. Richardson,Sarah E. Hudelson,Susan H. Eshleman,Kathleen George,Kathleen George,Mary Glenn Fowler,Paul Sato,Paul Sato,Lynne M. Mofenson,Lynne M. Mofenson +21 more
TL;DR: A TDF dosing regimen of 600 mg during labor and daily infant doses of 6 mg/kg maintains infant tenofovir plasma concentration above 50 ng/mL throughout the first week of life and should be used in the studies of TDF efficacy for HIV prevention of mother-to-child transmission and early infant treatment.
Journal ArticleDOI
Discovery of pyrroloaminopyrazoles as novel PAK inhibitors.
Chuangxing Guo,Indrawan James Mcalpine,Zhang Junhu,Daniel D. Knighton,Kephart Susan Elizabeth,M. Catherine Johnson,Li Haitao,Djamal Bouzida,Yang Anle,Dong Liming,Marakovits Joseph T,Tikhe Jayashree Girish,Paul G. Richardson,Lisa C. Guo,Robert Steven Kania,Martin Paul Edwards,Eugenia Kraynov,James G. Christensen,Joseph Piraino,Joseph K. T. Lee,Eleanor Dagostino,Christine Del-Carmen,Ya-Li Deng,Tod Smeal,Brion W. Murray +24 more
TL;DR: The efflux of the pyrrolopyrazole series was effectively reduced by applying multiple medicinal chemistry strategies, leading to a series of PAK inhibitors that are orally active in inhibiting tumor growth in vivo.
Journal ArticleDOI
Proteasome Inhibition: A Novel Approach to Anticancer Therapy
TL;DR: Preliminary data suggest that bortezomib inhibits proteasome activity in a dose-dependent and reversible manner, and has manageable toxicities.